



Development of NYC DEP's SARS-CoV-2 RNA Environmental Monitoring Program

John Dennehy, Monica Trujillo, Davida Smyth, Andrea Silverman, Catherine Hoar, Peter Williamsen, Francoise Chauvin, Esmeraldo Castro, Alexander Clare, Hope McGibbon, Samantha Patinella and Dimitri Katehis

Agenda

In the beginning...

Genetic signal concentration - Method development and data

Clinical data versus wastewater data

Sequencing

Concluding thoughts

Acknowledgments



NYC DEP team:

Vincent Sapienza
Pamela Elardo
Michael DeLoach
Dimitrios Katehis
Peter Williamsen
Françoise Chauvin
William Kelly
Esmeraldo (Alan) Castro
Alexander Clare
Hope McGibbon
Samantha Patinella
Naudet Joasil
Gina Behnke
Samantha MacBride
Jorge Villacis
Ira Elmore
Angie Kalicharan
Pedick Lai

CUNY team:

John Dennehy (Queens College)
Monica Trujillo (Queensborough CC)
Davida Smyth (The New School)

Krish Ramalingam (CCNY)

NYU team:


Andrea Silverman (NYU – Tandon School)
Catherine Hoar (NYU - Funded by the Alfred P. Sloan Foundation)

Overview


What we know:

- Viral presence in human GI tract and viral RNA (genetic material) can be shed in feces for about month
- Typically not present in urine
- Presence of Viral RNA different from Presence of Infectious Virus
 - No evidence of transmission from sewage

Coronaviruses with Lipid Bi-Layer



Typical Enteric Non-Enveloped Viruses with Protein Capsid



Overview

- Environmental Monitoring in Individual Sewersheds: a tool to identify infection trends in a population
- Examples: Samples for COVID-19 in Amsterdam and Paris using techniques developed for Polio, Norovirus and Hepatitis (capsid protected viruses)
- More research is needed to refine analytical techniques for coronavirus





Figure 1: Quantitative time-course monitoring of SARS-CoV2 in wastewater samples from Paris area





DEP Research and Development Efforts

A true partnership:

- Analytical method developed by CUNY
 - Plant influent
 - 3-day procedure
- Staff training provided by CUNY and NYU
- Procurement Support through CUNY
- Ongoing support from NYU and CUNY
 - Analytical support
 - Method extension
 - Data interpretation
 - Bridging to Microbial Source Tracking



Sampling program



Sample analysis workflow

Surrogate
Addition (BCoV)



Pasteurization



Solids separation

PEG
Addition

Day # 1


Overnight
incubation




Centrifugation
12,000g 120min
No brake



Manual
RNA extraction
Day # 2



Reverse Transcription
qPCR – BCoV




Reverse Transcription
qPCR – N1 and N2

Day # 3

Method developed by the CUNY team

RT-qPCR



Quality Control and Validation

- Positive control ("surrogate"):
 - Bovine coronavirus vaccine (BCoV) spiked into each sample.
 - Wide recovery range
- Negative controls:
 - Method blank = Type I water processed through the entire protocol – Acceptance criterion: non-detect
 - No Template Control = Type I water processed through RT-qPCR – Acceptance criterion: non-detect
- Duplicates:
 - One sample per batch is processed and analyzed in duplicate.
- PCR: all RNA extracts analyzed in triplicate


Reproducibility and sensitivity of 36 methods to quantify the SARS-CoV-2 genetic signal in raw wastewater: findings from an interlaboratory methods evaluation in the U.S.

Brian M. Pecson et al. (2020) Environ. Sci.: Water Res. Technol

“A nationwide interlaboratory comparison of methods for the quantification of SARS-CoV-2 genetic signal in wastewater showed a high degree of reproducibility. 80% of the results from eight method groups (36 different methods) fell within a band of approximately +/- 1-log GC/L.”

LoD and LoQ


- Limit of Detection: 4,500 copies/L
 - concentration that produces at least 95% positive replicates
- Limit of Quantitation: 15,000 copies/L
 - LoQ: lowest concentration where replicates show a $CV \leq 35\%$ on back calculated concentrations



NYC WRRFs Data → NYC DOHMH




Copies/day/population equivalent




- Plant ID
- 9/8/2020
- 9/13/2020
- 9/15/2020
- 9/20/2020
- 9/22/2020
- 9/27/2020
- 9/29/2020
- 10/4/2020
- 10/6/2020
- 10/11/2020
- 10/13/2020
- 10/18/2020
- 10/20/2020
- 10/25/2020
- 10/27/2020
- 11/1/2020
- 11/3/2020
- 11/8/2020
- 11/10/2020
- 11/15/2020
- 11/17/2020
- 11/22/2020
- 11/24/2020
- 11/29/2020
- 12/1/2020
- 12/6/2020
- 12/8/2020
- 12/13/2020
- 12/15/2020
- 12/20/2020
- 12/22/2020
- 12/27/2020
- 12/29/2020
- 1/3/2021
- 1/5/2021
- 1/10/2021
- 1/12/2021
- 1/17/2021
- 1/19/2021
- 1/24/2021
- 1/26/2021
- 1/31/2021
- 2/7/2021
- 2/14/2021
- 2/21/2021
- 2/28/2021
- 3/7/2021
- 3/14/2021
- 3/21/2021
- 3/28/2021
- 4/4/2021
- 4/11/2021
- 4/18/2021
- 4/25/2021
- 4/27/2021
- 5/2/2021
- 5/9/2021
- 5/11/2021
- 5/16/2021
- 5/18/2021
- 5/23/2021
- 5/25/2021
- 5/30/2021
- 6/1/2021
- 6/6/2021
- 6/8/2021
- 6/13/2021
- 6/15/2021
- 6/20/2021
- 6/22/2021
- 6/27/2021
- 6/29/2021


Data normalized by flow and population

Clinical data versus wastewater data



Clinical data versus wastewater data






Spearman's rank correlation coefficient (ρ)
significance levels

- * $\alpha = 0.05$
- ** $\alpha = 0.01$
- *** $\alpha = 0.001$
- **** $\alpha < 0.0001$

NEW COVID-19 cases/day (7-day average) vs. flow-normalized SARS-CoV-2 viral loads in wastewater (N1 GC/day)

Estimating LOD – number of cases / day



Estimated minimum detectable COVID-19 case rates reached May 2021, but viral RNA still detectable in wastewater. Possibly due to:

- Decreased COVID-19 testing rates?
- Asymptomatic and mild cases of vaccinated individuals?
- Prolonged fecal shedding of the virus?
- Limitations of methodology used for estimate?


Continuous improvement

- QA/QC - Standard used for RT-qPCR:
 - DNA
 - DNA – Linearized plasmid
 - RNA: Twist control
 - RNA: EURM-19 standard
 - Evaluation of inactivated ATCC SARS-CoV-2
- Variability study
- Normalization
 - BCoV
 - PMMoV (fecal marker)
- Automation and Analytical Capacity
 - 14 Slot Centrifuges (2) - Started with one centrifuge (6 slots)
 - QIAcube – Automated RNA extraction - enhance analytical consistency
 - Digital PCR – Reduce analytical noise and enhance data quality and PCR system throughput
- Staffing
 - Started with a single staff member
 - Currently 3 active staff and 1 back up



“We are building the boat as we are sailing it” - (CDC)


Sample analysis protocol - N1 – Improved



Targeted sequencing approach

S contains many mutations
of clinical relevance

E484A F486P Q493K S494P Q498Y H519N T572N



nested PCR amplifying the whole RBD
MiSeq



PCR amplifying 333 bp of the RBD
iSeq




Depth of coverage = Number of times a base is covered by sequencing

The more depth of coverage you have – the more certain you can be that the sequence is real

Identifying mutations and variants

15077 depth of coverage = average 15077 sequences covering the positions



Name ▲	Minimum	Maximum	Length	Change	Coverage	Polymorphism Type	Variant Frequency	Variant P-Value (approximate)	Amino Acid Change	CDS Position	Codon Change	Protein Effect
A	23,041	23,041	1	-A	8,392	Deletion	1.4%	1.0E-85		1,479		Frame Shift
A	22,874	22,874	1	T -> A	8,380	SNP (transversion)	1.5%	4.3E-185	S -> T	1,312	UCU -> ACU	Substitution
A	22,992	22,992	1	G -> A	8,282	SNP (transition)	1.6%	1.7E-180	S -> N	1,430	AGC -> AAC	Substitution
A	23,012	23,012	1	G -> A	8,439	SNP (transition)	16.2%	0.0	E -> K	1,450	GAA -> AAA	Substitution
C	23,042	23,042	1	T -> C	8,389	SNP (transition)	8.0%	0.0	S -> P	1,480	UCA -> CCA	Substitution
G	22,917	22,917	1	T -> G	8,445	SNP (transversion)	6.0%	0.0	L -> R	1,355	CUG -> CGG	Substitution
G	22,934	22,934	1	A -> G	8,443	SNP (transition)	1.7%	3.7E-217	K -> E	1,372	AAG -> GAG	Substitution
T	22,936	22,936	1	G -> T	8,374	SNP (transversion)	1.1%	1.6E-117	K -> N	1,374	AAG -> AAT	Substitution
T	23,063	23,063	1	A -> T	8,332	SNP (transversion)	9.0%	0.0	N -> Y	1,501	AAU -> TAU	Substitution


S477N
B.1.526

S494P
B.1.177.75, B.1.1.459, B.1.1.461, B.1.1.253,
B.1.595.3, B.1.1.451, B.1.476, B.1.1.174,
B.1.486, B.1.575, B.1.575.1


N501Y
B.1.351, B.1.1.7

Tracking variants with Wastewater


Clinical: Lineage distribution patient sequences




NYC February




NYC March




NYC April




NYC Wastewater: Lineage distribution WW Surveillance




WW February
(303,000 copies/L)



WW March
(21,000 copies/L)



WW April 5
(156,000 copies/L)



WW April 19
(33,000 copies/L)

Concluding Thoughts

- Environmental Surveillance: An opportunity to convert applied research to a public health tool
- The toolkit is still in its infancy – although many years of development have been condensed into the past 18 months
 - Significant progress in the analytical components of the toolkit
 - Still unclear how it will be fully leveraged by public health specialists
 - How strong of a predictive tool is it?
 - Sequencing for detection of variants being developed (CUNY/Queens College /The New School)
 - Epidemiology (NYU, DOHMH)
- Opportunities to apply it in other public health emergencies, including non-pandemic conditions

Overview

